MEF2B and neoplasm: These SMGs affect several well-known factors/pathways involved in lymphomagenesis, including chromatin modifiers (KMT2D, CREBBP, HIST1H1E, MEF2B, POU2F2, and EZH2), transcription factors (IRF8, FOXO1, EBF1, BCL6, and ETS1), immune modulators (TNFRSF14, CD70, and B2M), factors in the BCR/NF-κB pathway (CARD11, TNFAIP3, BCL10, CD79A/B, BTK, and KLHL6), NOTCH signaling pathway (KLF2, DTX1, NOTCH1/2, and SPEN), apoptosis (BCL2 and FAS), and tumor suppression (TP53).